Dr. Christiana Bardon
managing director of the Oncology Impact Fund
Dr. Christiana Bardon, a longtime booster of collaboration between large and small drugmakers in the oncology space, is in the right place at the right time. To wit, Congress has authorized $1.8 billion in funding over seven years for former Vice President Joe Biden’s Cancer Moonshot initiative, while the first generation of immuno-oncology therapies have captured the attention of physicians, patients, and payers alike.
In 2016, UBS Wealth Management raised $471 million for MPM’s Oncology Impact Fund (OIF), which Bardon oversees as managing director. OIF funds cancer research and access to cancer care in developing countries, investing in both private and public equities. Bardon is also portfolio manager of Burrage Capital, a healthcare equity fund.
Not surprisingly, Dr. Bardon is bullish on the sector. “We’re going to see ongoing progress from the big players — Bristol-Myers Squibb, Merck, and now Genentech,” she told Bloomberg last year. “These are going to be multibillion-dollar drugs. We’re also now going to see, in this era of combination drug development, some smaller biotech companies emerge.”